{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:24:31Z","timestamp":1793928271992,"version":"4.8.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["APSAN23GE0"],"award-info":[{"award-number":["APSAN23GE0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["BARTZ23GE0"],"award-info":[{"award-number":["BARTZ23GE0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["RODIGIG23GE0"],"award-info":[{"award-number":["RODIGIG23GE0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["MORAN23GE0"],"award-info":[{"award-number":["MORAN23GE0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["BIANCO23GE0"],"award-info":[{"award-number":["BIANCO23GE0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["GANDHI23GE0"],"award-info":[{"award-number":["GANDHI23GE0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1K23DK139457-01A1"],"award-info":[{"award-number":["1K23DK139457-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.eprac.2026.04.016","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:18:50Z","timestamp":1777587530000},"page":"1401-1408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cystic Fibrosis\u2013Related Diabetes: Pathophysiology, Spectrum of Glycemic Abnormalities, and Evolving Approaches to Screening"],"prefix":"10.1016","volume":"32","author":[{"given":"Jennifer","family":"Apsan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kajal","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Perdomo Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica E.","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara K.","family":"Bartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.eprac.2026.04.016_bib1","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1164\/rccm.201512-2518OC","article-title":"Abnormal glucose tolerance in infants and young children with cystic fibrosis","volume":"194","author":"Yi","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.eprac.2026.04.016_bib2","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/ppul.20619","article-title":"Predictors of mortality in adults with cystic fibrosis","volume":"42","author":"Courtney","year":"2007","journal-title":"Pediatr Pulmonol"},{"issue":"3 Pt 1","key":"10.1016\/j.eprac.2026.04.016_bib3","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1164\/ajrccm.162.3.9904075","article-title":"Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline","volume":"162","author":"Milla","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.eprac.2026.04.016_bib4","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/pedi.13453","article-title":"ISPAD Clinical Practice Consensus Guidelines 2022: management of cystic fibrosis-related diabetes in children and adolescents","volume":"23","author":"Ode","year":"2022","journal-title":"Pediatr Diabetes"},{"issue":"8","key":"10.1016\/j.eprac.2026.04.016_bib5","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1515\/jpem-2017-0005","article-title":"Cystic-fibrosis related-diabetes (CFRD) is preceded by and associated with growth failure and deteriorating lung function","volume":"30","author":"Terliesner","year":"2017","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.eprac.2026.04.016_bib6","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/BF01957574","article-title":"Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis","volume":"151","author":"Lanng","year":"1992","journal-title":"Eur J Pediatr"},{"issue":"2","key":"10.1016\/j.eprac.2026.04.016_bib7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcf.2019.10.009","article-title":"Cystic fibrosis related diabetes in Europe: prevalence, risk factors and outcome","volume":"19","author":"Olesen","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.eprac.2026.04.016_bib8","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2337\/dc25-0044","article-title":"Trends in cystic fibrosis-related diabetes epidemiology between 2003 and 2018 from the U.S. Cystic Fibrosis Foundation Patient Registry","volume":"48","author":"Kohler","year":"2025","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2026.04.016_bib9","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1164\/rccm.201403-0576OC","article-title":"Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex","volume":"191","author":"Lewis","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.eprac.2026.04.016_bib10","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.2337\/dc09-0585","article-title":"Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2026.04.016_bib11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000110206","article-title":"Long-term effect of insulin treatment in cystic fibrosis-related diabetes","volume":"76","author":"Mohan","year":"2008","journal-title":"Respiration"},{"issue":"2","key":"10.1016\/j.eprac.2026.04.016_bib12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2337\/dc09-1492","article-title":"Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain","volume":"33","author":"Hameed","year":"2010","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2026.04.016_bib13","first-page":"S11","article-title":"Standards of medical care in diabetes--2010","volume":"33","year":"2010","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2026.04.016_bib14","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1159\/000543033","article-title":"ISPAD Clinical Practice Consensus Guidelines 2024: type 2 diabetes in children and adolescents","volume":"97","author":"Shah","year":"2024","journal-title":"Horm Res Paediatr"},{"issue":"1","key":"10.1016\/j.eprac.2026.04.016_bib15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jcjd.2024.09.001","article-title":"Cystic fibrosis-related diabetes: a first Canadian Clinical Practice Guideline","volume":"49","author":"Coriati","year":"2025","journal-title":"Can J Diabetes"},{"issue":"1","key":"10.1016\/j.eprac.2026.04.016_bib16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jcf.2024.10.005","article-title":"Exogenous insulin does not reduce protein catabolism in pre-diabetic cystic fibrosis patients: a randomized clinical trial","volume":"24","author":"Schiavon","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"12","key":"10.1016\/j.eprac.2026.04.016_bib17","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"10.1016\/j.eprac.2026.04.016_bib18","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jcf.2019.08.016","article-title":"Cystic fibrosis related diabetes: pathophysiology, screening and diagnosis","volume":"18","author":"Granados","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.04.016_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/2042018820966428","article-title":"Retinopathy and microalbuminuria are common microvascular complications in cystic fibrosis-related diabetes","volume":"11","author":"Kempegowda","year":"2020","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2026.04.016_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17404-z","article-title":"Structural abnormalities in islets from very young children with cystic fibrosis may contribute to cystic fibrosis-related diabetes","volume":"7","author":"Bogdani","year":"2017","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.eprac.2026.04.016_bib21","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jcf.2019.01.009","article-title":"The main mechanism associated with progression of glucose intolerance in older patients with cystic fibrosis is insulin resistance and not reduced insulin secretion capacity","volume":"18","author":"Colomba","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.eprac.2026.04.016_bib22","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jcf.2022.03.010","article-title":"Obesity in Cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"12","key":"10.1016\/j.eprac.2026.04.016_bib23","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.2337\/dc10-1279","article-title":"Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2026.04.016_bib24","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1097\/HEP.0000000000000646","article-title":"Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations","volume":"79","author":"Sellers","year":"2024","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.eprac.2026.04.016_bib25","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.2337\/db13-0510","article-title":"Genetic modifiers of cystic fibrosis-related diabetes","volume":"62","author":"Blackman","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.eprac.2026.04.016_bib26","article-title":"CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy","volume":"30","author":"Crow","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2026.04.016_bib27","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/ppul.26388","article-title":"The impact of elexacaftor\/tezacaftor\/ivacaftor on body composition in a small cohort of youth with cystic fibrosis","volume":"58","author":"Granados","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.eprac.2026.04.016_bib28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1210\/clinem\/dgad443","article-title":"Preservation of beta-cell function in pancreatic insufficient cystic fibrosis with highly effective CFTR modulator therapy","volume":"109","author":"Flatt","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.eprac.2026.04.016_bib29","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1210\/clinem\/dgae857","article-title":"Glycemia and insulin secretion in cystic fibrosis 2 years after elexacaftor\/tezacaftor\/ivacaftor: PROMISE-ENDO","volume":"110","author":"Chan","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2026.04.016_bib30","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2021.09.001","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis","volume":"21","author":"Scully","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.eprac.2026.04.016_bib31","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/dc10-1604","article-title":"Elevation of 1-hour plasma glucose during oral glucose tolerance testing is associated with worse pulmonary function in cystic fibrosis","volume":"34","author":"Brodsky","year":"2011","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2026.04.016_bib32","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/pedi.12700","article-title":"\u03b2-Cell secretory defects are present in pancreatic insufficient cystic fibrosis with 1-hour oral glucose tolerance test glucose >\/=155 mg\/dL","volume":"19","author":"Nyirjesy","year":"2018","journal-title":"Pediatr Diabetes"},{"issue":"4","key":"10.1016\/j.eprac.2026.04.016_bib33","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1183\/09031936.05.00068104","article-title":"New criteria for impaired fasting glucose and screening for diabetes in cystic fibrosis","volume":"25","author":"Mueller-Brandes","year":"2005","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.eprac.2026.04.016_bib34","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2337\/dc09-0586","article-title":"Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2026.04.016_bib35","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1067\/mpd.2003.5","article-title":"Glucose intolerance in children with cystic fibrosis","volume":"142","author":"Solomon","year":"2003","journal-title":"J Pediatr"},{"issue":"7006","key":"10.1016\/j.eprac.2026.04.016_bib36","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1136\/bmj.311.7006.655","article-title":"Glucose tolerance in patients with cystic fibrosis: five year prospective study","volume":"311","author":"Lanng","year":"1995","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.eprac.2026.04.016_bib37","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMcp1103643","article-title":"Clinical practice. Diagnosis of diabetes","volume":"367","author":"Inzucchi","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.eprac.2026.04.016_bib38","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJM196908282810901","article-title":"Glucose intolerance in cystic fibrosis","volume":"281","author":"Handwerger","year":"1969","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.eprac.2026.04.016_bib39","doi-asserted-by":"crossref","first-page":"e4094","DOI":"10.1210\/clinem\/dgaa592","article-title":"One-hour oral glucose tolerance tests for the prediction and diagnostic surveillance of type 1 diabetes","volume":"105","author":"Simmons","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2026.04.016_bib40","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jcf.2013.06.001","article-title":"Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test","volume":"13","author":"Schmid","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.eprac.2026.04.016_bib41","doi-asserted-by":"crossref","first-page":"868","DOI":"10.2337\/dc11-2181","article-title":"Insulin sensitivity, beta-cell function, and incretin effect in individuals with elevated 1-hour postload plasma glucose levels","volume":"35","author":"Marini","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.04.016_bib42","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/4395556","article-title":"Predictive value of 1-hour glucose elevations during oral glucose tolerance testing for cystic fibrosis-related diabetes","volume":"2023","author":"Lorenz","year":"2023","journal-title":"Pediatr Diabetes"},{"issue":"2","key":"10.1016\/j.eprac.2026.04.016_bib43","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jcf.2019.05.005","article-title":"Peak OGTT glucose is associated with lower lung function in young children with cystic fibrosis","volume":"19","author":"Prentice","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.eprac.2026.04.016_bib44","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S2352-4642(25)00099-9","article-title":"Insulin for early glycaemic abnormality in children with cystic fibrosis without cystic fibrosis-related diabetes (CF-IDEA): a randomised controlled trial","volume":"9","author":"Hameed","year":"2025","journal-title":"Lancet Child Adolesc Health"},{"issue":"3","key":"10.1016\/j.eprac.2026.04.016_bib45","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1399-5448.2008.00451.x","article-title":"One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements","volume":"10","author":"Mozzillo","year":"2009","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.eprac.2026.04.016_bib46","article-title":"Impaired glucose tolerance and indeterminate glycemia in cystic fibrosis","volume":"26","author":"Kasim","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.eprac.2026.04.016_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1183288","article-title":"A provider survey of cystic fibrosis related diabetes screening and management practices at North American CF centers","volume":"14","author":"Hicks","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"10.1016\/j.eprac.2026.04.016_bib49","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1055\/a-1117-3771","article-title":"Glucose tolerance in patients with cystic fibrosis\u2014results from the German Cystic Fibrosis Registry","volume":"232","author":"Prinz","year":"2020","journal-title":"Klin Padiatr"},{"issue":"10","key":"10.1016\/j.eprac.2026.04.016_bib50","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.2337\/dci23-0036","article-title":"Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus","volume":"46","author":"Sacks","year":"2023","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2026.04.016_bib51","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2337\/dc09-9033","article-title":"International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes","volume":"32","year":"2009","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.eprac.2026.04.016_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112578","article-title":"High variability in oral glucose tolerance among 1,128 patients with cystic fibrosis: a multicenter screening study","volume":"9","author":"Scheuing","year":"2014","journal-title":"PLOS One"},{"issue":"2","key":"10.1016\/j.eprac.2026.04.016_bib53","doi-asserted-by":"crossref","first-page":"e548","DOI":"10.1210\/clinem\/dgab692","article-title":"The relationship between continuous glucose monitoring and OGTT in youth and young adults with cystic fibrosis","volume":"107","author":"Chan","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2026.04.016_bib54","doi-asserted-by":"crossref","first-page":"e1444","DOI":"10.1210\/clinem\/dgab857","article-title":"Continuous glucose monitoring and HbA1c in cystic fibrosis: clinical correlations and implications for CFRD diagnosis","volume":"107","author":"Scully","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.04.016_bib55","article-title":"Clinical practice versus guidelines for the screening of cystic fibrosis-related diabetes: a French survey from the 47 centers","volume":"28","author":"Weiss","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2026.04.016_bib56","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/thx.54.1.40","article-title":"Diagnosis of cystic fibrosis related diabetes: a selective approach in performing the oral glucose tolerance test based on a combination of clinical and biochemical criteria","volume":"54","author":"Yung","year":"1999","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.eprac.2026.04.016_bib57","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jcf.2015.03.013","article-title":"HbA1c as a screening tool for cystic fibrosis related diabetes","volume":"15","author":"Burgess","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.eprac.2026.04.016_bib58","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2016.02.005","article-title":"Glycated hemoglobin cannot yet be proposed as a screening tool for cystic fibrosis related diabetes","volume":"15","author":"Boudreau","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.eprac.2026.04.016_bib59","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jcjd.2021.03.005","article-title":"Glycated hemoglobin as a first-line screening test for cystic fibrosis\u2012related diabetes and impaired glucose tolerance in children with cystic fibrosis: a validation study","volume":"45","author":"Racine","year":"2021","journal-title":"Can J Diabetes"},{"issue":"1","key":"10.1016\/j.eprac.2026.04.016_bib60","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcjd.2018.04.008","article-title":"Cystic fibrosis-related diabetes screening in adults: a gap analysis and evaluation of accuracy of glycated hemoglobin levels","volume":"43","author":"Gilmour","year":"2019","journal-title":"Can J Diabetes"},{"issue":"8","key":"10.1016\/j.eprac.2026.04.016_bib61","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/pedi.12914","article-title":"Screening for cystic fibrosis-related diabetes and prediabetes: evaluating 1,5-anhydroglucitol, fructosamine, glycated albumin, and hemoglobin A1c","volume":"20","author":"Tommerdahl","year":"2019","journal-title":"Pediatr Diabetes"},{"issue":"11","key":"10.1016\/j.eprac.2026.04.016_bib62","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.2337\/dc22-0239","article-title":"Impact of HbA1c followed 32 years from diagnosis of type 1 diabetes on development of severe retinopathy and nephropathy: the VISS Study","volume":"45","author":"Arnqvist","year":"2022","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2026.04.016_bib63","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jcf.2017.05.010","article-title":"The use of fructosamine in cystic fibrosis-related diabetes (CFRD) screening","volume":"17","author":"Lam","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.eprac.2026.04.016_bib64","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2025.2514787","article-title":"Time to replace the oral glucose tolerance test for cystic fibrosis related diabetes first-step screening? Establishing glycemic tools relevant to cystic fibrosis","volume":"57","author":"Estey","year":"2025","journal-title":"Ann Med"},{"issue":"5","key":"10.1016\/j.eprac.2026.04.016_bib65","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jcf.2020.01.003","article-title":"Abnormal glucose tolerance and the 50-gram glucose challenge test in cystic fibrosis","volume":"19","author":"Sheikh","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.04.016_bib66","series-title":"Screening for Diabetes and pre-diabetes in CF using a non-fasting 50g 1 hour glucose challenge test","author":"Maher","year":"2025"},{"issue":"5","key":"10.1016\/j.eprac.2026.04.016_bib67","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jcf.2024.06.009","article-title":"Feasibility and accuracy of at-home glucose tolerance tests for cystic fibrosis related diabetes screening","volume":"23","author":"Alexandre-Heymann","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.eprac.2026.04.016_bib68","first-page":"1317","article-title":"Oral glucose tolerance testing using candy: a sweet solution to improve screening in children with cystic fibrosis?","volume":"10","author":"Weeks","year":"2023","journal-title":"Children (Basel)"},{"issue":"3","key":"10.1016\/j.eprac.2026.04.016_bib69","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1159\/000542786","article-title":"Feasibility of using continuous glucose monitoring to detect glycemic abnormalities in children with cystic fibrosis","volume":"99","author":"Leonard","year":"2026","journal-title":"Horm Res Paediatr"},{"issue":"6","key":"10.1016\/j.eprac.2026.04.016_bib70","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.2337\/dc08-1925","article-title":"Validation of continuous glucose monitoring in children and adolescents with cystic fibrosis: a prospective cohort study","volume":"32","author":"O'Riordan","year":"2009","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2026.04.016_bib71","article-title":"Can continuous glucose monitoring predict cystic fibrosis-related diabetes and worse clinical outcome?","volume":"48","author":"Zorron","year":"2022","journal-title":"J Bras Pneumol"},{"key":"10.1016\/j.eprac.2026.04.016_bib72","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1293709","article-title":"Continuous glucose monitoring and advanced glycation endproducts for prediction of clinical outcomes and development of cystic fibrosis-related diabetes in adults with CF","volume":"15","author":"Scully","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1016\/j.eprac.2026.04.016_bib73","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jcf.2025.11.003","article-title":"Continuous glucose monitoring is a better indicator of glucose tolerance than HbA1c in cystic fibrosis","volume":"25","author":"Alexandre-Heymann","year":"2026","journal-title":"J Cyst Fibros"},{"issue":"Suppl 2","key":"10.1016\/j.eprac.2026.04.016_bib74","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jcf.2019.08.025","article-title":"Continuous glucose monitoring in cystic fibrosis\u2014a practical guide","volume":"18","author":"Chan","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.eprac.2026.04.016_bib75","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.eprac.2026.04.016_bib76","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jcf.2023.11.005","article-title":"Decline in HbA1c during the first year of elexacaftor\/tezacaftor\/ivacaftor treatment in the Danish cystic fibrosis cohort: short title: decline in HbA1c after elexacaftor\/tezacaftor\/ivacaftor treatment","volume":"23","author":"Nielsen","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"11","key":"10.1016\/j.eprac.2026.04.016_bib77","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1210\/clinem\/dgaf099","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on glucose tolerance in adolescents with cystic fibrosis","volume":"110","author":"Galderisi","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2026.04.016_bib78","doi-asserted-by":"crossref","DOI":"10.1530\/EC-25-0690","article-title":"Elexacaftor-tezacaftor-ivacaftor enhances first-phase insulin secretion and improves glucose control in cystic fibrosis","volume":"15","author":"Edlund","year":"2026","journal-title":"Endocr Connect"},{"issue":"19","key":"10.1016\/j.eprac.2026.04.016_bib79","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26009638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26009638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:27:28Z","timestamp":1793924848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26009638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":78,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1530891X26009638"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.04.016","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cystic Fibrosis\u2013Related Diabetes: Pathophysiology, Spectrum of Glycemic Abnormalities, and Evolving Approaches to Screening","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of the AACE.","name":"copyright","label":"Copyright"}]}}